Biobase Lab Instruments Laboratories manufactures the www. biobase. cc reagents distributed by Genprice. The Www. Biobase. Cc reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Biobase lab Instruments. Other Www. products are available in stock. Specificity: Www. Category: Biobase. Group: Cc
CC-90003 |
|||
B2419-5 | Biovision | EUR 414 |
CC-115 |
|||
B2499-25 | Biovision | EUR 631 |
CC-115 |
|||
B2499-5 | Biovision | EUR 196 |
darkroom 254/254nm |
|||
VLCN15-CC | Consort | ea | EUR 1535 |
CC-401 (hydrochloride) |
|||
HY-13022 | MedChemExpress | 10mg | EUR 422 |
CC-115 (hydrochloride) |
|||
HY-16962A | MedChemExpress | 10mM/1mL | EUR 216 |
CC-401 hydrochloride |
|||
A3287-10 | ApexBio | 10 mg | EUR 538 |
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. |
CC-401 hydrochloride |
|||
A3287-5 | ApexBio | 5 mg | EUR 321 |
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. |
CC-401 hydrochloride |
|||
A3287-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 348 |
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. |
CC-401 hydrochloride |
|||
A3287-50 | ApexBio | 50 mg | EUR 1497 |
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. |
Lenalidomide (CC-5013) |
|||
A4211-100 | ApexBio | 100 mg | EUR 189 |
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. |
Lenalidomide (CC-5013) |
|||
A4211-250 | ApexBio | 250 mg | EUR 224 |
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. |
Lenalidomide (CC-5013) |
|||
A4211-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 113 |
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. |
Lenalidomide (CC-5013) |
|||
A4211-50 | ApexBio | 50 mg | EUR 154 |
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. |
Lenalidomide (CC-5013) |
|||
A4211-500 | ApexBio | 500 mg | EUR 258 |
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. |
Lenalidomide (CC-5013) |
|||
A4211-S | ApexBio | Evaluation Sample | EUR 81 |
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects. |
Pomalidomide (CC-4047) |
|||
A4212-10 | ApexBio | 10 mg | EUR 142 |
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM). |